Back to Research Center

Titan Medical

Catalyst Rich Titan Medical, Inching Towards Its David & Goliath Moment.

Over the next 24 months, Titan will be catalyst-rich. 2022 can be categorized as a clinical year for Titan, with an IDE approval and regular clinical trial updates throughout the year. 2023 will be a regulatory year, with a De Novo submission and potential FDA market authorization. We believe investors should, and will, ascribe higher valuations to Titan as it progresses through its clinical and then regulatory milestones. Read More.